Avatrombopag
As of the edition of 20 October 2026, Avatrombopag is a small molecule: marketed, first approved in 2018 (US); acts on MPL; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Doptelet
- First approved
- 21 May 2018 (US)
- Approvals on record
- 8 in 5 regions
- Holder of the most recent approval
- Akarx; 4 holders in all
- Registered trials
- 62, 7 stopped early
- Disease areas
- Blood and lymph; Immune system; Digestive system; Cancer; Infections; Skin and connective tissue
US protection
US protection ends in 2032.
The last listed US exclusivity ends in 2032. The application that gives this date is held by Akarx.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product7 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 7 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Avatrombopag.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MPL | Thrombopoietin receptor | P40238 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 3 | 1 | 1 |
| Phase 1 | 11 | 10 | 0 | 1 |
| Phase 2 | 19 | 6 | 3 | 2 |
| Phase 3 | 15 | 6 | 5 | 3 |
| Phase 4 | 7 | 2 | 1 | 0 |
| All trials | 62 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Swedish Orphan Biovitrum | Applicant and Lead sponsor of trials | 2018 to now |
| Akarx | Originator | 2018 to now |